3-bromocytisine and Disease-Models--Animal

Nicotinic acetylcholine receptor agonists are considered potential pharmacological agents for Parkinson's disease treatment, due to their ability to improve experimental Parkinson symptomatology, reduce 3,4-dihydroxy-L-phenylalanine-induced dyskinesias and stop the neurodegenerative process at an experimental level. In the present work, the ability of the nicotinic agonist cytisine and two halogenated derivatives (3-bromocytisine and 5-bromocytisine) to induce striatal dopamine release was characterized in vivo by microdialysis. Cytisine, 5-bromocytisine and nicotine were much more efficacious than 3-bromocytisine in eliciting dopamine release in response to their local application through the microdialysis probe. Moreover, the agonists were intermittently administered before and after an intranigral injection of 6-hydroxydopamine (6-OHDA), and striatal dopamine tissue levels were assessed 8 days after the lesion. Both cytisine and its 5-bromo derivative (but not the 3-bromo derivative) significantly prevented the decrease of striatal dopamine tissue levels induced by 6-OHDA. These results suggest that the efficacy of nicotinic agonists to stimulate dopamine release in vivo through presynaptic nicotinic receptors could be related to their potential to induce striatal protection.

Topics: Alkaloids; Animals; Antiparkinson Agents; Azocines; Bridged-Ring Compounds; Disease Models, Animal; Dopamine; Male; Microdialysis; Neostriatum; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinsonian Disorders; Quinolizines; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Receptors, Presynaptic; Substantia Nigra